Business
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled “Inside MEAI: New Insights from the CMND-100 Psychedelic C
About this update from Clearmind Medicine Inc.
[{"type":"image","alt":"Clearmind Medicine Inc.","displaySize":"","headline":null,"caption":"Clearmind Medicine Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":46,"url":"https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o_LPn1dYo7pUzNzxgMYnmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/o_LPn1dYo7pUzNzxgMYnmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY0/https://media.zenfs.com/en/globenewswire.com/e18eb6f6a6c8d81f644b0fcdb3ee6405","width":300,"height":46}},"lazy":false},{"type":"text","content":"Registration Now Open - Join the Live Webinar on June 10, 2026","length":62,"tagName":"p"},{"type":"text","content":"Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced it will host a live webinar titled “Inside MEAI: New Insights from the CMND-100 Psychedelic Clinical Trial” on Wednesday, June 10, 2026, from 4:00 PM to 5:00 PM IDT.","length":509,"tagName":"p"},{"type":"text","content":"Interested participants are invited to register and secure their spot in this exclusive session.","length":96,"tagName":"p"},{"type":"text","content":"The webinar will provide an in-depth review of the latest clinical data from the Company’s ongoing FDA-approved Phase I/IIa multi-center trial evaluating CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). ","length":279,"tagName":"p"},{"type":"text","content":"The webinar will feature presentations and discussions by leading clinical investigators from the CMND-100 multi-center trial. Dr. Anahita Bassir Nia, MD, an addiction psychiatrist and Assistant Professor of Psychiatry at the Yale School of Medicine, will share insights from the Yale trial site. Her research focuses on developing novel treatments for addiction and stress-related disorders, with a particular emphasis on cannabinoids and psychedelics. She...